Abstracts tagged "Disease Activity"

Abstract Number: 1810 • ACR Convergence 2020
Complement Activation in Systemic Lupus Erythematosus Patients with Low Disease Activity Is Not Inhibited by Hydroxychloroquine
Anne Margrethe Troldborg¹, Annette Hansen², Kristian Stengaard-Pedersen² and Steffen Thiel², ¹Aarhus University Hospital, Arhus, Denmark, ²Aarhus University, Aarhus, Denmark
Background/Purpose: Mortality in patients with systemic lupus erythematosus (SLE) is significantly higher than in the general population. Treatment of SLE patients has improved, however, a…
Abstract Number: 1984 • ACR Convergence 2020
Causal Pathways to Health-Related Quality of Life in Children with Juvenile Idiopathic Arthritis: Results from the ReACCh-Out Cohort
Kiem Oen¹, Jiahao Tian², Thomas Loughin², Roberta Berard³, Mercedes Chan⁴, Ciaran Duffy⁵, Brian Feldman⁶, Adam Huber⁷, Deborah Levy⁸, Dax G. Rumsey⁹, Natalie Shiff¹⁰, Shirley Tse¹¹, Lori Tucker⁴, Karen Watanabe-Duffy⁵ and Jaime Guzman¹², ¹University of Manitoba, Toronto, ON, Canada, ²Simon Fraser University, Burnaby, BC, Canada, ³London Health Sciences Centre, London, ON, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵Children's Hospital of Eastern Ontario, Ottawa, ON, Canada, ⁶The Hospital for Sick Children, Toronto, ON, Canada, ⁷Dalhousie University, Halifax, NS, Canada, ⁸Division of Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ⁹University of Alberta, Edmonton, AB, Canada, ¹⁰Florida, Gainesville, FL, ¹¹SickKids, Toronto, ON, Canada, ¹²University of British Columbia and BC Children's Hospital, Vancouver, BC, Canada
Background/Purpose: The relative roles of disease activity and disability as determinants of health-related quality of life (HRQoL) in children with JIA have been controversial; sometimes…
Abstract Number: 0169 • ACR Convergence 2020
Patient-Reported Outcomes Differentiate Between Remission and Low Disease Activity in Psoriatic Arthritis
Juliette Yedimenko¹, Jessica Walsh², Alexis Ogdie³, Yuxuan Jin¹, Soumya Reddy⁴, Jose Scher⁵ and M. Elaine Husni¹, ¹Cleveland Clinic, Cleveland, OH, ²University of Utah School of Medicine, George E. Wahlen Veteran Affairs Medical Center, Salt Lake City, UT, ³Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁴NYU School of Medicine, New York, NY, ⁵NYU School of Medicine, New York City
Background/Purpose: For psoriatic arthritis (PsA), several different composite instruments are available to define low disease activity (LDA) and remission (REM) targets for treatment. Patient-reported outcomes…
Abstract Number: 0313 • ACR Convergence 2020
Swollen Joints but Not Tender Joints Are Associated with Ultrasound Power Doppler Synovitis in Very Early DMARD Naive Psoriatic Arthritis
Sayam Dubash¹, Oras Alabas¹, Xabier Michelena¹, Leticia Garcia-Montoya¹, Gabriele De Marco², Mira Merashli³, Richard Wakefield¹, Philip Helliwell⁴, Ai Lyn Tan¹, Dennis McGonagle¹, Paul Emery⁵ and Helena Marzo-Ortega¹, ¹The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, ²The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Treviglio, Italy, ³The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Beirut, Lebanon, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, UK, Leeds, United Kingdom
Background/Purpose: Clinical tender and swollen joint counts are used for biologic drug eligibility and clinical trial inclusion criteria. Ultrasonography (US) adds to clinical examination as…
Abstract Number: 0616 • ACR Convergence 2020
Correlation Between Disease Activity and Perceived Economic Barriers to Care in a Population of African American Women with Systemic Lupus Erythematosus
Ashley White¹, Trevor Faith¹, Aissatou Ba¹, Viswanathan Ramakrishnan², Hetlena Johnson³, Jillian Rose⁴, Clara Dismuke-Greer⁵, Jim Oates⁶, Leonard Egede⁷ and Edith Williams¹, ¹Medical University of South Carolina, Charleston, SC, ²medical university of south carolina, south carolina, ³LupusCSC, Columbia, SC, ⁴Hospital for Special Surgery, New York, ⁵Palo Alto VA, Palo Alto, CA, ⁶Medical University of South Carolina, Charleston, SC, Charleston, SC, ⁷Medical College of Wisconsin, Milwaukee, WI
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a complex, multifactorial disease with heterogeneous presentation. Disease activity – the number and severity of symptoms – can be…
Abstract Number: 0828 • ACR Convergence 2020
Clinical and Functional Response to Tofacitinib in Patients with Rheumatoid Arthritis: Probability Plot Analysis of Results from a Phase 3b/4 Methotrexate Withdrawal Study
Stanley B Cohen¹, Yi-Hsing Chen², Naonobu Sugiyama³, Jose L Rivas⁴, Annette Diehl⁵, Tatjana Lukic⁶, Jerome Paulissen⁷, Haiyun Fan⁵, Tomohiro Hirose³ and Edward C Keystone⁸, ¹Metroplex Clinical Research Center, Dallas, TX, ²Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer SLU, Madrid, Spain, ⁵Pfizer Inc, Collegeville, PA, ⁶Pfizer Inc, New York, NY, ⁷Syneos Health, Morrisville, NC, ⁸Mount Sinai Hospital, Toronto, ON, Canada
Background/Purpose: ORAL Shift (NCT02831855) was a 48-week Phase 3b/4 study, which demonstrated sustained efficacy/safety of tofacitinib modified release 11 mg once daily (QD) following MTX…
Abstract Number: 0983 • ACR Convergence 2020
Outcomes Following Antimalarial Withdrawal in Patients with Quiescent Systemic Lupus Erythematosus
Danae Papachristos¹, Dafna Gladman², Jiandong Su³ and Murray Urowitz⁴, ¹University Health Network, Toronto, ON, Canada, ²Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto Lupus Clinic, Centre for Prognosis Studies in Rheumatic Diseases, Toronto Western Hospital, University Health Network, Toronto, ON, Canada, ⁴University Health Network, University of Toronto, Toronto, ON, Canada
Background/Purpose: Antimalarial medications (AMs) are central to the management of SLE, affording numerous clinical benefits including the reduction of disease flare. However, little is known…
Abstract Number: 1229 • ACR Convergence 2020
Blood Lymphocyte Subsets for Early Identification of Non-Remission to TNF Inhibitors in Rheumatoid Arthritis
Eulalia Rodriguez-Martín¹, Israel Nieto-Gañán¹, Borja Hernández-Breijo², Cristina Sobrino³, Carlota García-Hoz¹, Javier Bachiller-Corral⁴, Ana Martínez-Feito⁵, Victoria Navarro-Compán⁶, Paloma Lapuente-Suanzes¹, Gema Bonilla⁷, Dora Pascual-Salcedo⁸, Garbiñe Roy¹, Teresa Jurado², Pilar Nozal², Mónica Vázquez⁴, Alejandro Balsa⁷, Luisa M Villar¹ and Chamaida Plasencia⁷, ¹Hospital Universitario Ramón y Cajal-IRYCIS, Madrid, Spain, ²Hospital Universitario La Paz-Idipaz, Madrid, Spain, ³Hospital Ramón y Cajal-IRYCIS, Madrid, Spain, ⁴Rheumatology, Hospital Universitario Ramón y Cajal, Madrid, Spain, ⁵Hospital Unversitario La Paz- idipaz, Madrid, Spain, ⁶Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, ⁷Rheumatology, La Paz University Hospital-IdiPAZ, Madrid, Spain, ⁸Hospital Universitario La Paz- Idipaz, Madrid, Spain
Background/Purpose: TNF inhibitors (TNFis) are widely used for the treatment of rheumatoid arthritis (RA), although the response rates to this therapy in patients with RA…
Abstract Number: 1362 • ACR Convergence 2020
BASDAI Guided Treat-to-target Tapering of Tumor Necrosis Factor Inhibitors in Axial Spondyloarthritis: Results of the Retrospective TAPAS Study
Nathan den Broeder¹, Michelle Mulder¹, Mark Wenink¹, Alfons den Broeder¹, Lise Verhoef², Frank van den Hoogen¹ and C.A.J Michielsens¹, ¹Sint Maartenskliniek, Nijmegen, Netherlands, ²Sint Maartenskliniek, Nijmegen, Gelderland, Netherlands
Background/Purpose: Tumor Necrosis Factor inhibitors (TNFi) have proven to be safe and effective in the treatment of axial spondyloarthritis (axSpA). However, they carry some disadvantages,…
Abstract Number: 1723 • ACR Convergence 2020
RA Flare Prediction via Machine Learning and Algorithm Based on SSDM Big Data
Yan Zhao¹, Rong Mu², Xiaomei Li³, Hongsheng Sun⁴, Cundong Mi⁵, Guosheng Wang³, Shengqian Xu⁶, Minghua Xu⁷, Haiying Chen⁸, Qingchun Huang⁹, Ling Lei¹⁰, HaiLi Shen¹¹, Hui Xiao¹², Yuhua Jia¹³, Bing Wu¹³, Xin Chen¹², Shengsong Jia¹² and Fei Xiao¹³, ¹Peking Union Medical College hospital, Beijing, Beijing, China (People's Republic), ²People's Hospital, Beijing University Medical School, Beijing, Beijing, China (People's Republic), ³the First Affiliated Hospital of University of Science and Technology of China, Hefei, Anhui, China (People's Republic), ⁴Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China (People's Republic), ⁵The Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ⁶the First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China (People's Republic), ⁷Affiliated Hospital of Hebei University, Baoding, Hebei, China (People's Republic), ⁸The Third Affiliated Hospital of Hebei Medical University, Shijiazhuang, Hebei, China (People's Republic), ⁹Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, Guangdong, China (People's Republic), ¹⁰The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), ¹¹Second Hospital of Lanzhou University, Lanzhou, Gansu, China (People's Republic), ¹²Shanghai Gothic Internet Technology Co., Ltd., Shanghai, Shanghai, China (People's Republic), ¹³Shanghai Gothic Internet Technology Co., Ltd., Shanghai, China (People's Republic)
Background/Purpose: Flare, relapse from status of treat-to-target (T2T, DAS28< =3.2), is hard predicted. We try to make it predictable by applying machine learning to a…
Abstract Number: 1816 • ACR Convergence 2020
Urine Biomarkers of Tubulointersitital Damage in Lupus Nephritis
Brianna Lally¹, Shudan Wang², Sammy Chalmers³, Wenzhu Mowrey³, Tamar Rubinstein⁴, Beatrice Goilav⁵ and Anna Broder⁶, ¹Albert Einstein College of Medicine, Bronx, NY, ²Albert Einstein College of Medicine, New York, NY, ³Albert Einstein College of Medicine, Bronx, ⁴Albert Einstein College of Medicine / Montefiore Medical Center, White Plains, NY, ⁵The Children’s Hospital at Montefiore, Albert Einstein College of Medicine, Bronx, NY, ⁶Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, NY
Background/Purpose: Tubulointerstitial disease (TID), defined as tubulointerstitial inflammation (TII) or interstitial fibrosis/tubular atrophy (IFTA), is associated with progression to end stage renal disease (ESRD) in…
Abstract Number: 1991 • ACR Convergence 2020
Abatacept Treatment Reduces Cutaneous and Joint Activity in Juvenile Localized Scleroderma
Suzanne Li¹, Sarah Ishaq², Mary Buckley³, Kathryn Torok⁴, Barbara Edelheit⁵, Kaleo Ede⁶, Christopher Liu⁷ and C. Egla Rabinovich⁸, ¹Hackensack University Medical Center, Hackensack, ²Montclair State University, Montclair, ³Duke University, Durham, NC, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵Conneticut Children's Medical Center, Hartford, ⁶Phoenix Children's Hospital, Phoenix, AZ, ⁷U Pittsburgh, Pittsburgh, ⁸Duke University Hospital, Durham, NC
Background/Purpose: Juvenile localized scleroderma (jLS) is an autoimmune disease commonly associated with damage. Damage includes dyspigmentation, tissue atrophy, arthropathy, hemiatrophy, vision loss, and seizures. To…
Abstract Number: 0186 • ACR Convergence 2020
The Number of Associated Comorbidities Can Impact Disease Activity Scores Independently from Objective Measures of Inflammation in Patients with Rheumatoid Arthritis
Magali Zanotti-Cavazzoni¹ and Gabriela Avila², ¹Sociedad Paraguaya de Reumatología, Asunción, Paraguay, ²Sociedad Paraguaya de Reumatologia, Asuncion, Paraguay
Background/Purpose: Disease activity scores (DAS) are used as tools to assess persistent inflammation and need for therapeutic escalation in patients with Rheumatoid arthritis (RA). One…
Abstract Number: 0315 • ACR Convergence 2020
The Role of Ultrasound for the Assessment of Psoriatic Arthritis Patients with Fibromyalgia
Ari Polachek¹, Victoria Furer², Mirna Zureik³, Sharon Nevo³, Liran Mendel⁴, David Levartovsky², Jonathan Wollman³, Valerie Aloush², Mark Berman², Ilana Kaufman⁵, Reut Tzemach⁴, Marina Anouk⁶, Ofir Elalouf⁷, Hagit Padova⁴, Or Carmi⁸, Tali Eviatar⁹, Yael Lahat goldstein², Hagit Sarbagil-Maman¹⁰, Sara Borok Lev-Ran², Adi Broide³, Lihi Eder¹¹, Daphna Paran² and Ori Elkayam³, ¹Tel Aviv Sourasky Medical Center, Petah-Tikva, Israel, ²Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ³Tel Aviv Sourasky Medical Center, Tel-Aviv, Israel, ⁴Souraaky Medical Center, Tel-Aviv, Israel, ⁵Tel Aviv Sourasky Medical Center, Petah-Tiqwa, Israel, ⁶Souraaky Medical Center, Tel Aviv, Israel, ⁷Souraaky Medical Center, Herzliya, Israel, ⁸Souraaky Medical Center, herzelia, Israel, ⁹Tel Aviv Sourasky Medical Center, Givataim, Israel, ¹⁰Tel-Aviv Sourasky Medical Center, Kiryat Ono, Israel, ¹¹University of Toronto, Toronto, ON, Canada
Background/Purpose: The presence of fibromyalgia (FMS) in psoriatic arthritis (PsA) patients increases the scores of the clinical measures of disease activity. The aim of this…
Abstract Number: 0721 • ACR Convergence 2020
Validation of New Antirheumatic Drug Use as a Proxy for Increased JIA Disease Activity
Avinash Gabbeta¹, Evan Mulvihill², Timothy Beukelman³, James Lewis⁴, Carlos Rose⁵, Brian Strom⁶ and Daniel Horton⁷, ¹St. Christopher's Hospital for Children, Philadelphia, PA, ²Nemours A.I. duPont Hospital for Children, Wilmington, DE, ³University of Alabama at Birmingham, Birmingham, AL, ⁴University of Pennsylvania, Philadelphia, PA, ⁵Nemours A.I. duPont Hospital for Children, Wilmingon, DE, ⁶Rutgers University, Newark, NJ, ⁷Rutgers University, New Brunswick, NJ
Background/Purpose: Administrative claims databases are valuable tools for studying treatment effects in large JIA populations but do not contain direct measures of disease activity, limiting…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].